SPARC and cancer: Four genes (CDH13, CYB5R2, RARB2 and SPARC) showed the expected significant hypermethylation (p < 0.05) in cancer patients compared with HDs, whereas DRD2 and LINE-1 were hypomethylated (p < 0.05), as anticipated.